Elite Pharmaceuticals delivers record second-quarter fiscal 2026 earnings as lisdexamfetamine sales surged, though margins faced competitive pressure.
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q2 2026 Earnings Call November 17, 2025 11:30 AM EST Company Participants Nasrat Hakim - Chairman, CEO & President Carter Ward - CFO, Secretary & Treasurer Presentation Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Second Quarter of Fiscal Year 2026 Conference Call. [Operator Instructions] Before management begins speaking, the conference has the following statement.
Elite Pharmaceuticals reports strong first-quarter fiscal 2026 results with rising direct sales, higher-margin products and expanding gross profit.
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Nasrat Hakim CEO | OTCQB Exchange | US28659T2006 ISIN |
| US Country | 53 Employees | - Last Dividend | - Last Split | 23 Jul 1998 IPO Date |
Elite Pharmaceuticals, Inc. is a distinguished specialty pharmaceutical company focused on the development, manufacturing, and marketing of oral, controlled-release, and generic pharmaceuticals. The company is actively involved in two major pharmaceutical segments: Abbreviated New Drug Applications (ANDAs) for Generic Pharmaceuticals and New Drug Applications (NDAs) for Branded Pharmaceuticals. Since its inception in 1997, Elite Pharmaceuticals has been committed to providing advanced therapeutic solutions and has established itself as a player in the pharmaceutical industry with a robust product portfolio and a pipeline of developed drugs. Headquartered in Northvale, New Jersey, Elite Pharmaceuticals strives to address the needs of patients across various therapeutic areas with its innovative drug delivery technologies and manufacturing capabilities.
Elite Pharmaceuticals offers a comprehensive range of generic and branded pharmaceutical products targeting a variety of therapeutic areas. The company leverages its expertise in oral dose pharmaceuticals to serve the bariatric, pain management, cardiovascular, central nervous system, muscle relaxant, antipsychotic, and antibiotic sectors, among others. Below is an outline of their key products and services:
In addition to its comprehensive portfolio, Elite Pharmaceuticals actively engages in the contract manufacturing of controlled-release products for third-party clients, covering pain, allergy, bariatric, attention deficit, and infection therapies. Furthermore, the company is at the forefront of developing abuse-deterrent opioid products, reflecting its commitment to addressing the ongoing opioid crisis while meeting medical needs.